New drug combo aims to shrink returning gynecologic tumors

NCT ID NCT03968406

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Feb 22, 2026 · Last updated May 16, 2026 · Updated 10 times

Summary

This early-stage study tests a drug called talazoparib together with radiation therapy for people whose gynecologic cancer (like ovarian, endometrial, or cervical) has returned after previous treatment. The main goal is to find the safest dose and see how well the combination works at shrinking tumors. About 24 participants will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Johns Hopkins University/Sidney Kimmel Cancer Center
RECRUITING

Baltimore, Maryland, 21287, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
M D Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.